Gleason Score for Prostate Cancer
Prognoses prostate cancer based on microscopic tumor appearance.
CreatorThe dominant pattern of the tumor (>50% of total pattern seen)
Introduction
The Gleason score is the main way of grading prostate cancer, showing how aggressive the cancer cells look under a microscope. Donald F. Gleason, MD, a pathologist at the Veterans Administration hospital in Minneapolis, developed it in the 1960s. It has been updated several times by the International Society of Urological Pathology (ISUP), most recently in 2014. The Grade Group system, introduced in 2016 by Jonathan Epstein, MD, and colleagues, translates Gleason scores into five simpler groups, which many pathology reports now list alongside, or instead of, the Gleason score. The grade is one of the most important factors in deciding prostate cancer treatment, together with PSA level, cancer stage, and MRI findings.
How it’s reported
The pathologist identifies three patterns:
Primary grade: The dominant pattern of the tumor (>50% of total pattern seen).
Secondary grade: The highest grade pattern seen after the primary pattern.
Tertiary grade: Small component of a third (generally more aggressive) pattern.
Each grade is given a score from 1-5.
1+ Closely resembles normal prostate. Glands are small, well-formed, closely packed.
2+ Increased stroma with well-formed glands, but larger with more tissue between them.
3+ Recognizable glands, but cells are darker. Some cells have left the glands and are beginning to invade the surrounding tissue or have an infiltrative pattern.
4+ Few recognizable glands. Many cells invading the surrounding tissue clumps.
5+ Few or no recognizable glands. Often sheets of cells throughout the surrounding tissue.
How it's scored
The primary and secondary grades are summed together and assigned a prognostic grade grouping.
Grading System:
Gleason Score | Prognostic Grade Group |
|---|---|
Gleason score ≤6: | Group I: Unlikely severe cancer is present. Consider close monitoring. |
Gleason score 3 + 4 = 7: | Group II: 90.6% and 93.6% remission of tumor within 2 years of diagnosis. |
Gleason score 4 + 3 = 7: | Group III: < 90.6% remission of tumor within 2 years of diagnosis. |
Gleason score 8: | Group IV: 70.9% - 73.7% remission of tumor within 2 years of diagnosis. |
Gleason score 9-10: | Group V: 66.7% - 58.5% remission of tumor within 2 years of diagnosis. |
Results
In this example, if the primary grade is 1, the secondary grade is 3, and the tertiary grade is 4, the following result will appear:
1+3=4 Gleason Score, Tertiary Grade: 4
Prognostic grade group 1: Unlikely severe cancer is present. Consider close monitoring.
Limitations
The Gleason score and Grade Group describe the cancer sample the pathologist examined. A biopsy can miss more aggressive areas, so the grade can sometimes rise when the whole prostate is examined after surgery. Pathology reports may also include details that refine risk, such as the percentage of pattern 4 or the presence of cribriform glands, which aren’t captured by the score alone. The grade is only one part of the picture. Treatment decisions also depend on PSA level, tumor stage, MRI findings, the number of biopsy cores involved, overall health, and personal preferences. This tool explains a pathology result; it doesn’t replace a discussion with a urologist or oncologist.
All questions & possible results
Pattern gradesTitle not visible
Primary grade
The dominant pattern of the tumor (>50% of total pattern seen)
Select one option:
- Closely resembles normal prostate. Glands are small, well-formed, closely packed.
- Increased stroma with well-formed glands, but larger with more tissue between them.
- Recognizable glands, but cells are darker. Some cells have left the glands and are beggining to invade the surrounding tissue or have an infiltrative pattern.
- Few recognizable glands. Many cells invading the surrounding tissue clumps.
- Few or no recognizable glands. Often sheets of cells throughout the surrounding tissue.
Secondary grade
The highest grade pattern seen after the primary pattern
Select one option:
- Closely resembles normal prostate. Glands are small, well-formed, closely packed.
- Increased stroma with well-formed glands, but larger with more tissue between them.
- Recognizable glands, but cells are darker. Some cells have left the glands and are beggining to invade the surrounding tissue or have an infiltrative pattern.
- Few recognizable glands. Many cells invading the surrounding tissue clumps.
- Few or no recognizable glands. Often sheets of cells throughout the surrounding tissue.
Tertiary grade
Small component of a third (generally more aggressive) pattern
Select one option:
- Closely resembles normal prostate. Glands are small, well-formed, closely packed.
- Increased stroma with well-formed glands, but larger with more tissue between them.
- Recognizable glands, but cells are darker. Some cells have left the glands and are beggining to invade the surrounding tissue or have an infiltrative pattern.
- Few recognizable glands. Many cells invading the surrounding tissue clumps.
- Few or no recognizable glands. Often sheets of cells throughout the surrounding tissue.
Possible results
Prognostic Grade II: 90.6% and 93.6% remission of tumor within 2 years of diagnosis.
Predominantly well-formed glands with a lesser component of poorly formed, fused or cribriform glands. Favorable intermediate-risk disease.
Prognostic Grade III: <90.6% remission of tumor within 2 years of diagnosis.
Predominantly poorly formed, fused or cribriform glands with a lesser component of well-formed glands. Unfavorable intermediate-risk disease.
Prognostic Grade IV: 70.9%-73.7% remission of tumor within 2 years of diagnosis.
Only poorly formed, fused or cribriform glands; or predominantly well-formed glands with a lesser component lacking glands; or predominantly lacking glands with a lesser component of well-formed glands. High-risk disease.
Prognostic Grade V: 66.7%-58.5% remission of tumor within 2 years of diagnosis.
Lacks gland formation (or with necrosis), with or without poorly formed, fused or cribriform glands. Highest-risk disease.
Prognostic Grade I: Unlikely severe cancer is present. Consider close monitoring.
Only individual, discrete well-formed glands. Lowest-risk disease; commonly managed with active surveillance depending on clinical stage, PSA and extent of disease.
Citation
Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013 May;111(5):753-60.
Literature
Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013 May;111(5):753-60.
https://pubmed.ncbi.nlm.nih.gov/23464824/Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005 Sep;29(9):1228-42.
https://pubmed.ncbi.nlm.nih.gov/16096414/
- Creator
Dr. Donald F. Gleason, MD, PhD(d.2009) Former chief of pathology at the Minneapolis VA Medical Center. Served as a lieutenant in the Army Medical Corps. Received both the American Urological Association's Presidential Citation Award and an Outstanding Achievement Award from the University of Minnesota.
- Provided by
EVAL Foundation
- Contributor · Reviewer
Jennifer Glen, DNP, FNP-BCEVAL Health, Chief Medical Officer EVAL Foundation